AI-powered insights from the Veradigm Network reveal real-world GLP-1 outcomes hidden in EHR data CHICAGO--(BUSINESS ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound; Eli Lilly) ...

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.

Among people with obesity or overweight, tirzepatide users lost 20.2% of body weight compared with a 13.7% loss with semaglutide over 72 weeks. Participants on tirzepatide also lost 5.4 cm more in ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

In our clinical update of the month, clinical editor Caroline Price unpacks the rollout and clinical challenges of weight-loss drug tirzepatide (brand name Mounjaro) with GP and editorial adviser Dr ...